What Happened?

Cancer patients who take their treatment as a pill can pay $10,000 to $12,000 or more out of pocket each year, while patients who get the same type of drug through an IV drip often pay far less. The House Oversight Subcommittee on Health Care and Financial Services examined that gap on Sept. 15, hearing testimony on why oral cancer drug costs run so much higher for patients despite the drugs often being equally effective. [](#ngr-fd18702c-ede6-41c4-996b-cfd0d88de4de)

Pills are billed under pharmacy benefits, which carry higher patient cost-sharing. IV drugs given in a clinic are billed under medical benefits, which typically cost patients less. The Food and Drug Administration has approved more than 50 oral anti-cancer medications, and between a quarter and a third of cancer drugs now in development are expected to be available only as pills.

Why Does it Matter to Me?

If you or a family member is being treated for cancer, the form your drug comes in can determine whether your out-of-pocket costs run into the thousands. More than 40 states have passed laws requiring insurers to treat oral and IV chemotherapy equally, but those rules don't apply to self-funded employer health plans, which cover roughly half of all cancer patients.

That means a large share of Americans have no protection against the cost gap, regardless of where they live. Anthony Wright of Families USA, a health advocacy group, testified that oral chemotherapy affordability connects directly to broader coverage losses affecting patients.

Both Sides, Now

Rep. Glenn Grothman (R-WI) introduced the Cancer Drug Parity Act on a bipartisan basis. The bill would require health plans to cover oral anticancer drugs on terms no less favorable than IV treatment. Sens. Jerry Moran and Tina Smith introduced a companion bill in July. The International Myeloma Foundation, the Association for Clinical Oncology, and the American Cancer Society Cancer Action Network all back the legislation.

Rep. Emily Randall (D-WA), filling in as the subcommittee's ranking Democrat, raised a broader concern: she noted that up to 10 million people are estimated to have already lost health coverage, and that the administration canceled $160 million in funding for Washington state disease monitoring and vaccine programs. The nonpartisan Congressional Budget Office projects that new Medicaid work rules will lead to 11.8 million people dropping Medicaid over the next decade, with 7 million of them not finding insurance elsewhere. The administration has pointed to pharmacy benefit manager reforms included in the Consolidated Appropriations Act, 2026, signed in February, and has promoted drug pricing initiatives, though an NPR investigation found that key oral cancer medications were not available on the administration's TrumpRx pricing platform.

What Happens Next?

This was the first hearing on high drug costs held by the subcommittee in nine months. No follow-up hearings or votes on the Cancer Drug Parity Act are currently scheduled. For the bill to become law, it would need to clear committee, pass both the House and Senate, and be signed by the president.

---

This article was generated by AI pulling from data. Each article is edited by an editor for accuracy and clarity.

---

Spot something wrong? Report an issue with this article